DE60118195D1 - Modulatoren von protein tyrosin phosphatasen (ptpasen) - Google Patents

Modulatoren von protein tyrosin phosphatasen (ptpasen)

Info

Publication number
DE60118195D1
DE60118195D1 DE60118195T DE60118195T DE60118195D1 DE 60118195 D1 DE60118195 D1 DE 60118195D1 DE 60118195 T DE60118195 T DE 60118195T DE 60118195 T DE60118195 T DE 60118195T DE 60118195 D1 DE60118195 D1 DE 60118195D1
Authority
DE
Germany
Prior art keywords
protein tyrosine
tyrosine phosphatases
ptpases
modulators
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60118195T
Other languages
English (en)
Other versions
DE60118195T2 (de
Inventor
Sune Andersen
Kruse Hansen
Jesper Lau
Hundahl Moller
Hvilsted Olsen
Urban Axe
Farid Bakir
Yu Ge
Dale Holsworth
Milburn Judge
James Newman
Teruyuki Uyeda
Zvi Shapira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Ontogen Corp
Original Assignee
Novo Nordisk AS
Ontogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS, Ontogen Corp filed Critical Novo Nordisk AS
Publication of DE60118195D1 publication Critical patent/DE60118195D1/de
Application granted granted Critical
Publication of DE60118195T2 publication Critical patent/DE60118195T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
DE60118195T 2000-07-07 2001-06-28 Modulatoren von protein tyrosin phosphatasen (ptpasen) Expired - Fee Related DE60118195T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200001068 2000-07-07
DK200001068 2000-07-07
PCT/DK2001/000451 WO2002004459A1 (en) 2000-07-07 2001-06-28 Modulators of protein tyrosine phosphatases (ptpases)

Publications (2)

Publication Number Publication Date
DE60118195D1 true DE60118195D1 (de) 2006-05-11
DE60118195T2 DE60118195T2 (de) 2006-12-14

Family

ID=8159610

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118195T Expired - Fee Related DE60118195T2 (de) 2000-07-07 2001-06-28 Modulatoren von protein tyrosin phosphatasen (ptpasen)

Country Status (6)

Country Link
EP (1) EP1301516B1 (de)
JP (1) JP2004502775A (de)
AT (1) ATE321052T1 (de)
AU (1) AU2001270475A1 (de)
DE (1) DE60118195T2 (de)
WO (1) WO2002004459A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007099A (es) 1999-01-13 2002-03-27 Univ New York State Res Found Metodo novedoso para disenar inhibidores de la proteina cinasa.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
JP4623962B2 (ja) * 2001-10-22 2011-02-02 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼおよびホスファターゼ阻害剤、それらを設計する方法、ならびにそれらを使用する方法
CN1646508A (zh) 2002-04-03 2005-07-27 诺瓦提斯公司 作为ptp酶1b抑制剂的5－取代的1,1－二氧代－1,2,5－噻二唑烷－3－酮衍生物
MXPA05011539A (es) 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
US7358364B2 (en) * 2003-04-30 2008-04-15 The Institute For Pharmaceutical Discovery Llc Substituted carboxylic acids
WO2005081954A2 (en) 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
AU2005231980B2 (en) * 2004-04-07 2011-09-08 Merck Serono Sa 1,1'-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
JP2008520692A (ja) * 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
CN114478430B (zh) * 2022-02-21 2023-11-28 山东大学 一组芽孢噻唑类化合物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046267A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
WO1999046237A1 (en) * 1998-03-12 1999-09-16 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
JP2002506073A (ja) * 1998-03-12 2002-02-26 ノボ ノルディスク アクティーゼルスカブ プロテイン・チロシン・ホスファターゼ（ＰＴＰａｓｅｓ）のモジュレーター
AU2713799A (en) * 1998-03-12 1999-09-27 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (ptpases)
JP2003509430A (ja) * 1999-09-10 2003-03-11 ノボ ノルディスク アクティーゼルスカブ プロテインチロシンホスファターゼ（ｐｔｐアーゼ）のモジュレーター
DE60028791T2 (de) * 1999-09-10 2007-05-24 Novo Nordisk A/S Modulatoren der protein tyrosin phosphatase (ptpases)
AU7476800A (en) * 1999-09-10 2001-04-10 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48

Also Published As

Publication number Publication date
WO2002004459A1 (en) 2002-01-17
ATE321052T1 (de) 2006-04-15
AU2001270475A1 (en) 2002-01-21
EP1301516A1 (de) 2003-04-16
JP2004502775A (ja) 2004-01-29
EP1301516B1 (de) 2006-03-22
DE60118195T2 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE329920T1 (de) Modulatoren der protein tyrosin phosphatase (ptpases)
ATE309250T1 (de) Modulatoren der protein tyrosin phosphatase (ptpases)
ATE321052T1 (de) Modulatoren von protein tyrosin phosphatasen (ptpasen)
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
BR9913532A (pt) Novos inibidores heteroaromáticos de frutose 1,6-bifosfatase
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
DK1268847T3 (da) Ubiquitin-ligaseassay
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
TW200602337A (en) Inhibitors of protein tyrosine phosphatase 1B
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
SE0001899D0 (sv) New compounds
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
ATE363280T1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
NO20043259L (no) Bindingsproteiner som biosensorer
DE69941429D1 (de) 1-deoxy-galactonojirimycin-derivate zur vewendung bei der behandlung von lysosomalen speicherkrankheiten mittels steigerung der lysosomalen alpha galactosidase a
MY136764A (en) Indole-3-carboxamides as glucokinase (gk) activators
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
BR0316324A (pt) Polipeptìdeos e conjugados de interferon-alfa
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
TR200003071T2 (tr) Sistein-proteazı önleyici etkiye sahip yeni heterosiklik ikame edilmiş amidler
EA200400708A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
BRPI0302496B8 (pt) composições farmacêuticas com atividade antibiótica
DE60012140D1 (de) Verwendung von urintrypsininhibitor zur diagnose von aids
ATE295737T1 (de) Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel
TR200402650T4 (tr) Yeni positif alosterik ampa-reseptör modülatörleri (paarm), bunların imalatı için yöntem ve bunların ilaç olarak kullanımları

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee